92 related articles for article (PubMed ID: 15895681)
1. Structural requirements for inhibitors of cytochromes P450 2B: assessment of the enzyme interaction with diamondoids.
Hodek P; Bortek-Dohalská L; Sopko B; Sulc M; Smrcek S; Hudecek J; Janků J; Stiborová M
J Enzyme Inhib Med Chem; 2005 Feb; 20(1):25-33. PubMed ID: 15895681
[TBL] [Abstract][Full Text] [Related]
2. Use of Phenoxyaniline Analogues To Generate Biochemical Insights into the Interactio n of Polybrominated Diphenyl Ether with CYP2B Enzymes.
Chen C; Liu J; Halpert JR; Wilderman PR
Biochemistry; 2018 Feb; 57(5):817-826. PubMed ID: 29215266
[TBL] [Abstract][Full Text] [Related]
3. Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles.
Spatzenegger M; Wang Q; He YQ; Wester MR; Johnson EF; Halpert JR
Mol Pharmacol; 2001 Mar; 59(3):475-84. PubMed ID: 11179442
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-activity relationships (QSARs) for inhibitors and substrates of CYP2B enzymes: importance of compound lipophilicity in explanation of potency differences.
Lewis DF; Ito Y; Lake BG
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):679-84. PubMed ID: 20100069
[TBL] [Abstract][Full Text] [Related]
5. Probing the cytochrome P-450 2B1 active site with diamantoid compounds.
Hodek P; Burkhard J; Janků J
Gen Physiol Biophys; 1995 Jun; 14(3):225-39. PubMed ID: 8586256
[TBL] [Abstract][Full Text] [Related]
6. Structural analysis of binding of a diamantoid substrate to cytochrome P450 2B4: possible role of Arg 133 in modulation of function and activity of this enzyme.
Sulc M; Hudecek J; Stiborova M; Hodek P
Neuro Endocrinol Lett; 2008 Oct; 29(5):722-7. PubMed ID: 18987581
[TBL] [Abstract][Full Text] [Related]
7. New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen.
Stiborová M; Borek-Dohalská L; Hodek P; Mráz J; Frei E
Arch Biochem Biophys; 2002 Jul; 403(1):41-9. PubMed ID: 12061800
[TBL] [Abstract][Full Text] [Related]
8. Quantitative structure-activity relationships (QSARs) within cytochromes P450 2B (CYP2B) subfamily enzymes: the importance of lipophilicity for binding and metabolism.
Lewis DF; Lake BG; Ito Y; Anzenbacher P
Drug Metabol Drug Interact; 2006; 21(3-4):213-31. PubMed ID: 16841514
[TBL] [Abstract][Full Text] [Related]
9. Mapping of cytochrome P450 2B4 substrate binding sites by photolabile probe 3-azidiamantane: identification of putative substrate access regions.
Hodek P; Karabec M; Sulc M; Sopko B; Smrcek S; Martínek V; Hudecek J; Stiborová M
Arch Biochem Biophys; 2007 Dec; 468(1):82-91. PubMed ID: 17961497
[TBL] [Abstract][Full Text] [Related]
10. Subacute nicotine co-exposure has no effect on 2,2',3,5',6- pentachlorobiphenyl disposition but alters hepatic cytochrome P450 expression in the male rat.
Stamou M; Uwimana E; Flannery BM; Kania-Korwel I; Lehmler HJ; Lein PJ
Toxicology; 2015 Dec; 338():59-68. PubMed ID: 26463278
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of a dietary phytochemical 3,3'-diindolylmethane on the phenobarbital-induced hepatic CYP mRNA expression and CYP-catalyzed reactions in female rats.
Parkin DR; Lu Y; Bliss RL; Malejka-Giganti D
Food Chem Toxicol; 2008 Jul; 46(7):2451-8. PubMed ID: 18486294
[TBL] [Abstract][Full Text] [Related]
12. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytochrome P450 2B4 by environmentally persistent free radical-containing particulate matter.
Reed JR; dela Cruz AL; Lomnicki SM; Backes WL
Biochem Pharmacol; 2015 May; 95(2):126-32. PubMed ID: 25817938
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.
Chun J; Kent UM; Moss RM; Sayre LM; Hollenberg PF
Drug Metab Dispos; 2000 Aug; 28(8):905-11. PubMed ID: 10901699
[TBL] [Abstract][Full Text] [Related]
15. A structural snapshot of CYP2B4 in complex with paroxetine provides insights into ligand binding and clusters of conformational states.
Shah MB; Kufareva I; Pascual J; Zhang Q; Stout CD; Halpert JR
J Pharmacol Exp Ther; 2013 Jul; 346(1):113-20. PubMed ID: 23633618
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms.
Harleton E; Webster M; Bumpus NN; Kent UM; Rae JM; Hollenberg PF
J Pharmacol Exp Ther; 2004 Sep; 310(3):1011-9. PubMed ID: 15121764
[TBL] [Abstract][Full Text] [Related]
17. Identification of selective mechanism-based inactivators of cytochromes P-450 2B4 and 2B5, and determination of the molecular basis for differential susceptibility.
Strobel SM; Szklarz GD; He Y; Foroozesh M; Alworth WL; Roberts ES; Hollenberg PF; Halpert JR
J Pharmacol Exp Ther; 1999 Jul; 290(1):445-51. PubMed ID: 10381811
[TBL] [Abstract][Full Text] [Related]
18. Induction and inhibition of mouse cytochrome P-450 2B enzymes by musk xylene.
Lehman-McKeeman LD; Johnson DR; Caudill D
Toxicol Appl Pharmacol; 1997 Jan; 142(1):169-77. PubMed ID: 9007046
[TBL] [Abstract][Full Text] [Related]
19. Thermodynamic fidelity of the mammalian cytochrome P450 2B4 active site in binding substrates and inhibitors.
Muralidhara BK; Sun L; Negi S; Halpert JR
J Mol Biol; 2008 Mar; 377(1):232-45. PubMed ID: 18241887
[TBL] [Abstract][Full Text] [Related]
20. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
Peng CC; Rushmore T; Crouch GJ; Jones JP
Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
